B of A Securities Maintains Buy on Amicus Therapeutics, Lowers Price Target to $13

Benzinga · 05/10 11:42
B of A Securities analyst Tazeen Ahmad maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and lowers the price target from $14 to $13.